Icon (NASDAQ:ICLR) Shares Unloaded Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Icon Plc (NASDAQ:ICLR). In a filing disclosed on September 01st, the Representative disclosed that they had sold between $15,001 and $50,000 in Icon stock on August 14th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Home Depot (NYSE:HD) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Procter & Gamble (NYSE:PG) on 8/24/2026.
• Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 8/21/2026.
• Sold $15,001 – $50,000 in shares of Honeywell Aerospace (NASDAQ:HONA) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Colgate-Palmolive (NYSE:CL) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 8/18/2026.

Icon Stock Down 1.0%

Shares of NASDAQ:ICLR opened at $159.84 on Thursday. Icon Plc has a 52-week low of $66.57 and a 52-week high of $203.91. The company has a market capitalization of $12.24 billion, a PE ratio of 37.52, a price-to-earnings-growth ratio of 6.68 and a beta of 1.20. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. The company has a fifty day moving average of $168.10 and a 200-day moving average of $134.82.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.Icon’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted $3.26 EPS. On average, equities analysts predict that Icon Plc will post 9.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Icon

Several institutional investors have recently modified their holdings of the business. EFG International AG bought a new stake in Icon during the fourth quarter worth $27,000. Abound Financial LLC bought a new position in Icon in the 4th quarter valued at $54,000. GAMMA Investing LLC increased its position in shares of Icon by 21.4% during the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after purchasing an additional 69 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Icon during the 3rd quarter valued at $71,000. Finally, Blue Trust Inc. raised its stake in shares of Icon by 207.5% during the 1st quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock worth $73,000 after purchasing an additional 444 shares during the period. 95.61% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ICLR. Robert W. Baird set a $194.00 price target on shares of Icon in a research report on Friday, July 31st. Bank of America boosted their price target on Icon from $125.00 to $150.00 and gave the company an “underperform” rating in a research note on Thursday, June 25th. Piper Sandler cut shares of Icon to a “neutral” rating in a research report on Thursday, May 28th. Royal Bank Of Canada raised shares of Icon from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $126.00 to $185.00 in a research report on Thursday, June 25th. Finally, Mizuho raised their price target on shares of Icon from $180.00 to $190.00 and gave the company an “outperform” rating in a research report on Friday, June 26th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $170.40.

Insiders Place Their Bets

In other news, Director Anne Clem Whitaker sold 841 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $138,167.89. Following the completion of the sale, the director owned 891 shares in the company, valued at $146,382.39. This trade represents a 48.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ronan Martin Murphy sold 841 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total value of $138,167.89. Following the completion of the sale, the director owned 3,847 shares in the company, valued at approximately $632,023.63. The trade was a 17.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 9,531 shares of company stock valued at $1,565,764. Company insiders own 44.00% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.